Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2041 to 2055 of 8933 results

  1. Dronabinol for treating muscle spasticity in multiple sclerosis after 2 treatments [TSID10638]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Tirzepatide for treating type 2 diabetes [ID3938]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  3. Heart failure - sacubitril valsartan [ID822]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  4. Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  5. Empagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  6. Ertugliflozin in a triple therapy regimen for treating type 2 diabetes [ID1160]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  7. Ertugliflozin as monotherapy and in dual therapy for treating type 2 diabetes [ID1158]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  8. Dapagliflozin in triple therapy regimens for treating type 2 diabetes [ID962]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  9. Diabetes (type 2) - canagliflozin, dapagliflozin and empagliflozin (monotherapy) [ID756]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  10. Dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  11. Canagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  12. Dapagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

    Technology appraisal guidance
    In consultation

  13. Ciclosporin (Vevizye) eye drops for treating moderate to severe keratoconjunctivitis [TSID12293]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Bladder EpiCheck for the detection of bladder cancer recurrence (MT706)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  15. Artificial Intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: Early Value Assessment: draft guidance

    We are listening to your views on this Health technology evaluation. Comments close 24 February 2026.

    Health technology evaluation
    In consultation